牛二龙;张毅;李阳;张扬;覃君慧;梁媛;王瑞安;桑宏勋;

• 1:第四军医大学西京医院骨科
• 2:第四军医大学病理学与病理生理学教研室

摘要(Abstract)：

[目的]检测不同浓度低剂量阿司匹林对去势后(OVX)大鼠骨髓基质干细胞成骨分化的影响。[方法]建立SD大鼠去势模型,全骨髓贴壁法培养骨髓基质干细胞(BMSCs),传代4次后进行成骨诱导,建立对照组和不同浓度阿司匹林组(0.25、0.5、1、2及5mmol/L)。于不同的培养时间点,倒置显微镜观察并进行MTT检测细胞增殖生长情况;碱性磷酸酶(ALP)试剂盒检测培养细胞上清ALP活性;于诱导7d和21d时分别行细胞碱性磷酸酶染色和茜素红钙化结节染色。[结果]阿司匹林无明显促进BMSCs增殖作用,而大剂量阿司匹林(5 mmol/L)具有抑制BMSCs增殖作用。实验组(0.25、0.5、1、2 mmol/L阿司匹林组)细胞培养上清中ALP浓度较对照组显著增强(P<0.05);碱性磷酸酶染色(1、2 mmol/L组)阳性表达增强;茜素红染色显示,实验组(0.5、1、2mmol/L组)钙结节数量、钙化面积均高于对照组(P<0.05)。[结论]阿司匹林不能直接促进去势大鼠BMSC增殖活性,但小剂量阿司匹林可显著提高体外培养BMSC成骨活性,增强钙盐沉积,促进钙结节形成。

关键词(KeyWords)： 阿司匹林;去势大鼠;骨髓基质干细胞;成骨分化

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(编号:81270959)

作者(Author): 牛二龙;张毅;李阳;张扬;覃君慧;梁媛;王瑞安;桑宏勋;

Email:

DOI:

参考文献(References)：

• [1]Retornaz F,Seux V,Pauly V,et al.A fracture-intervention programoptimizes the management of osteoporosis[J].Geriatr Psychol Neuro-psychiatr Vieil,2011,4:437-444.
• [2]Carbone LD,Tylavsky FA,Cauley JA,et al.Association between bonemineral density and the use of nonsteroidal anti-inflammatory drugsand aspirin:impact of cyclooxygenase selectivity[J].J Bone MinerRes,2003,18:1795-1802.
• [3]Vestergaard P,Hermann P,Jensen JE,et al.Effects of paracetamol,non-steroidal anti-inflammatory drugs,acetylsalicylic acid,and opi-oids on bone mineral density and risk of fracture:results of the Dan-ish Osteoporosis Prevention Study(DOPS)[J].Osteoporos Int,2012,4:1255-1265.
• [4]Yamaza T,Miura Y,Bi Y,et al.Pharmacologic stem cell based inter-vention as a new approach to osteoporosis treatment in rodents[J].PLoS One,2008,7:2615-2624.
• [5]陈志文,吴子祥,桑宏勋,等.阿司匹林治疗大鼠绝经后骨质疏松的实验研究[J].中华医学杂志,2011,13:925-929.
• [6]冯靖,桑宏勋,白建萍,等.阿司匹林对体外培养骨髓间质细胞成骨性分化的影响[J].现代生物医学进展,2011,3:448-451,488.
• [7]Torremade BJ,Rodriguez TJ,Roman RI,et al.Testosterone-deficiencyas a risk factor for hip fracture in eldery men[J].Actas Urol Esp,2013,3:142-146.
• [8]Krum SA,Miranda-Carboni GA,Hauschka PV,et al.Estrogen pro-tects bone by inducing Fas ligand in osteoblasts to regulate osteoclastsurvival[J].EMBO,2008,3:535-545.
• [9]Cagnetta V,Patella V.The role of the immune system in the physio-pathology of osteoporosis[J].Clin Cases Miner Bone Metab,2012,2:85-88.
• [10]Roggia C,Gao Y,Cenci S,et al.Up-regulation of TNF-producing Tcells in the bone marrow:a key mechanism by which estrogen defi-ciency induces bone loss in vivo[J].Proc Natl Acad Sci USA,2001,24:13960-13965.
• [11]Blackman M R,Muniyappa R,Wilson M,et al.Diurnal secretion ofgrowth hormone,cortisol,and dehydroepi and rosterone in pre-andperimenopausal women with active rheumatoid arthritis:a pilot case-control study[J].Arthritis Res Ther,2007,4:73.
• [12]Nazrun AS,Norazlina M,Norliza M,et al.The anti-inflammatory roleof vitamin e in prevention of osteoporosis[J].Adv Pharmacol Sci,2012,12:142702.
• [13]Feng X.Regulatory roles and molecular signaling of TNF family mem-bers in osteoclasts[J].Gene,2005,1:1-13.
• [14]Wijenayaka AR,Kogawa M,Lim HP,et al.Sclerostin stimulates os-teocyte support of osteoclast activity by a RANKL-dependent pathway[J].PLoS One,2011,10:25900.
• [15]Liu XH,Kirschenbaum A,Yao S,et al.Cross-talk between the inter-leukin-6 and prostaglandin E2 signaling systems results in enhance-ment of osteoclastogenesis through effects on the osteoprotegerin/re-ceptor activator of nuclear factor-kappa B(RANK)ligand/RANKsystem[J].Endocrinology,2005,4:1991-1998.
• [16]Varenna M,Gatti D.The role of rank-ligand inhibition in the treat-ment of postmenopausal osteoporosis[J].Reumatismo,2010,3:163-171.
• [17]Smith J R,Pochampally R,Perry A,et al.Isolation of a highly clono-genic and multipotential subfraction of adult stem cells from bonemarrow stroma[J].Stem Cells,2004,5:823-831.
• [18]Alok D,Hassin S,Sampath Kumar R,et al.Characterization of a pitu-itary GnRH-receptor from a perciform fish,Morone saxatilis:func-tional expression in a fish cell line[J].Mol Cell Endocrinol,2000,1-2:65-75.
• [19]Howard D,Partridge K,Yang X,et al.Immunoselection and adenovi-ral genetic modulation of human osteoprogenitors:in vivo bone forma-tion on PLA scaffold[J].Biochem Biophys Res Commun,2002,2:208-215.
• [20]Chen JL,Guo ZK,Xu C,et al.Mesenchymal stem cells suppress allo-geneic T cell responses by secretion of TGF-beta1[J].Zhongguo ShiYan Xue Ye Xue Za Zhi,2002,4:285-288.
• [21]Hung SC,Chen NJ,Hsieh SL,et al.Isolation and characterization ofsize-sieved stem cells from human bone marrow[J].Stem Cells,2002,3:249-258.
• [22]Dong S W,Ying D J,Duan X J,et al.Bone regeneration using an a-cellular extracellular matrix and bone marrow mesenchymal stem cellsexpressing Cbfa1[J].Biosci Biotechnol Biochem,2009,10:2226-2233.
• [23]Pittenger MF,Mackay AM,Beck SC,et al.Multilineage potential ofadult human mesenchymal stem cells[J].Science,1999,5411:143-147.
• [24]Valenti MT,Dalle CL,Donatelli L,et al.Gene expression analysis inosteoblastic differentiation from peripheral blood mesenchymal stemcells[J].Bone,2008,6:1084-1092.
• [25]McQuillan DJ,Richardson MD,Bateman JF.Matrix deposition by acalcifying human osteogenic sarcoma cell line(SAOS-2)[J].Bone,1995,4:415-426.
• [26]Park JB.The effects of dexamethasone,ascorbic acid,and beta-glyc-erophosphate on osteoblastic differentiation by regulating estrogen re-ceptor and osteopontin expression[J].J Surg Res,2012,1:99-104.